On July 8, 2025, Silexion Therapeutics Corp reported that Nasdaq granted their request to remain listed, but their ordinary shares will be moved to the Nasdaq Capital Market, with potential issues regarding compliance if their share price stays below $1. A 1-for-15 reverse share split is planned to remedy this, pending shareholder approval on July 14, 2025.